PD-L1 is an imperfect predictive biomarker and there is concerted effort to incorporate other biomarkers [e.g., tumor mutation burden (TMB), tumor-infiltrating lymphocytes] to enhance patient selection, particularly for immune checkpoint inhibitor monotherapy (25–27). Here, CD274 is linked to neoplasm.